Health Affairs, 24, no. 6 (2005): 1571-1581 doi: 10.1377/hlthaff.24.6.1571 © 2005 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by Hayward, R. A. Articles by Hofer, T. P. Search for Related Content PubMed PubMed Citation Articles by Hayward, R. A. Articles by Hofer, T. P. Related Collections Consumer Issues Evidence-Based Medicine Legal/Regulatory Issues Research And Technology Politics

Using Evidence

Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers

Results of randomized clinical trials are the preferred "evidence" for establishing the benefits and safety of medical treatments. We present evidence suggesting that the conventional approach to reporting clinical trials has fundamental flaws that can result in overlooking identifiable subgroups harmed by a treatment while underestimating benefits to others. A risk-stratified approach can dramatically reduce the chances of such errors. Since professional and economic incentives reward advocating treatments for as broad a patient population as possible, we suggest that payers and regulatory bodies might need to act to motivate prompt, routine adoption of risk-stratified assessments of medical treatments’ safety and benefits.

                      What's this?

This article has been cited by other articles:

				E. A Kerr and B. Fleming Making performance indicators work: experiences of US Veterans Health Administration BMJ, November 10, 2007; 335(7627): 971 - 973. [Full Text] [PDF]

				D. M. Kent and R. A. Hayward Limitations of Applying Summary Results of Clinical Trials to Individual Patients: The Need for Risk Stratification JAMA, September 12, 2007; 298(10): 1209 - 1212. [Full Text] [PDF]

				K. A. Hepner, M. Rowe, K. Rost, S. C. Hickey, C. D. Sherbourne, D. E. Ford, L. S. Meredith, and L. V. Rubenstein The Effect of Adherence to Practice Guidelines on Depression Outcomes Ann Intern Med, September 4, 2007; 147(5): 320 - 329. [Abstract] [Full Text] [PDF]

				S. P. Glasser, M. Salas, and E. Delzell Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems J. Clin. Pharmacol., September 1, 2007; 47(9): 1074 - 1086. [Abstract] [Full Text] [PDF]

				L. V. Rubenstein, N. R. Rayburn, E. B. Keeler, D. E. Ford, K. M. Rost, and C. D. Sherbourne Predicting Outcomes of Primary Care Patients With Major Depression: Development of a Depression Prognosis Index Psychiatr Serv, August 1, 2007; 58(8): 1049 - 1056. [Abstract] [Full Text] [PDF]

				D. M. Kent, T. H. Jafar, R. A. Hayward, H. Tighiouart, M. Landa, P. de Jong, D. de Zeeuw, G. Remuzzi, A.-L. Kamper, A. S. Levey, et al. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1959 - 1965. [Abstract] [Full Text] [PDF]

				R. A. Hayward Performance Measurement in Search of a Path N. Engl. J. Med., March 1, 2007; 356(9): 951 - 953. [Full Text] [PDF]

				M. E. Chernew, A. B. Rosen, and A. M. Fendrick Value-Based Insurance Design Health Aff., March 1, 2007; 26(2): w195 - w203. [Abstract] [Full Text] [PDF]

				D. M. Kent and M. D. Hill Differences in Response to Reperfusion Therapies in Acute Stroke Between Men and Women: Mediated by Sex or by Chance? Stroke, December 1, 2006; 37(12): 2878 - 2879. [Full Text] [PDF]

				D. M. Kent, H. P. Selker, R. Ruthazer, E. Bluhmki, and W. Hacke Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window? Stroke, December 1, 2006; 37(12): 2963 - 2969. [Abstract] [Full Text] [PDF]

				R. A. Hayward, T. P. Hofer, and S. Vijan Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med, October 3, 2006; 145(7): 520 - 530. [Abstract] [Full Text] [PDF]

				D. M. Kent Stroke -- An Equal Opportunity for the Initiation of Statin Therapy N. Engl. J. Med., August 10, 2006; 355(6): 613 - 615. [Full Text] [PDF]

				J. B. Perlin and L. M. Pogach Improving the Outcomes of Metabolic Conditions: Managing Momentum To Overcome Clinical Inertia Ann Intern Med, April 4, 2006; 144(7): 525 - 527. [Full Text] [PDF]